Cell and gene therapy access in Asia

Published on June 27, 2024

/**/

Explore how cell and gene therapies (CGTs) are accessing major Asian markets. Our experts share insights on market-specific strategies and innovative reimbursement models that are shaping healthcare and driving better growth in Asia.

Cell and gene therapies (CGTs) have seen vibrant development across Asia, with nine chimeric antigen receptors (CAR) T cell therapies and four gene therapies available across major markets today. These innovative therapies have been proactively exploring different access and reimbursements approaches tailored to each market, with different levels of success to date. 

To date, a total of 9 CAR-T cell therapies and 4 gene therapies have been approved in Asian markets
  • Reimbursed
  • Approved but not Reimbursed​
  • Not available / approved​
 BrandManufacturerJapanSouth KoreaTaiwanChinaCAR-T…

CGTAccess in Asia

Continue reading on website
Other news

Achieving Sales Excellence: Empower tech sales teams for success

June 25, 2024
The core principle of Tech companies has shifted from pursuing growth at any cost to prioritizing sustainable, profitable growth. Recognizing the limitations of relying solely on cost-cutting, Tech companies now emphasize on maximizing revenue streams. Sales teams play a pivotal role, yet a significant percentage—60-80%—underperform due to a lack of Sales Excellence. Achieving true Sales Excellenc

Key priorities for FMCG companies in 2024: Europeanization of sales and pricing

July 2, 2024
The year 2023 was difficult for many FMCG companies. Revenues increased, but against lower volumes and lower profits. 2024 is anticipated to be another challenging year ahead.We discuss key actions that FMCG manufacturers should prioritize to face rapid market changes on a European level.Key challenges for FMCG companies in 2024There is a lingering uncertainty in consumer confidence. Consumers are